Literature DB >> 1716974

Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua.

K Nishikawa1, S Saito, T Morii, K Hamada, H Ako, N Narita, M Ichijo, M Kurahayashi, K Sugamura.   

Abstract

Most human peripheral blood natural killer (NK) cells express the phenotype CD16+CD56+. However, a very minor subset of NK cells express CD16-CD56+, and these NK cells bear both interleukin 2 receptor (IL-2R)alpha (p55) and IL-2R beta (p75) (high affinity IL-2 receptors). In this report, we demonstrate that in human early pregnancy decidua--an interface between maternal immunocompetent cells and fetus (placenta)--abundant (approximately 83%) CD16-CD56+ NK cells with high affinity IL-2 receptors were present, and these cells responded to low amounts of IL-2 (4.5 pM). These CD16-CD56+ NK cells significantly expressed an early activation antigen, CD69, in vivo, whereas peripheral CD16-CD56+ NK cells did not express CD69. These findings suggest that CD16-CD56+ NK cells in early pregnancy decidua may be activated in vivo, and may play an important role in immunoregulation during early pregnancy. Also, decidual lymphocytes may be useful materials to study the mechanism of MHC-unrestricted cytotoxicity of this type of NK cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716974     DOI: 10.1093/intimm/3.8.743

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  18 in total

1.  Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.

Authors:  T A Fehniger; E M Bluman; M M Porter; E Mrózek; M A Cooper; J B VanDeusen; S R Frankel; W Stock; M A Caligiuri
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  Chemokine ligand and receptor expression in the pregnant uterus: reciprocal patterns in complementary cell subsets suggest functional roles.

Authors:  K Red-Horse; P M Drake; M D Gunn; S J Fisher
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 3.  Chemokine expression and function at the human maternal-fetal interface.

Authors:  Penelope M Drake; Kristy Red-Horse; Susan J Fisher
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

4.  A novel surface molecule of Th2- and Tc2-type cells, CRTH2 expression on human peripheral and decidual CD4+ and CD8+ T cells during the early stage of pregnancy.

Authors:  H Tsuda; T Michimata; M Sakai; K Nagata; M Nakamura; S Saito
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

5.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Authors:  Bibiana Bielekova; Marta Catalfamo; Susan Reichert-Scrivner; Amy Packer; Magdalena Cerna; Thomas A Waldmann; Henry McFarland; Pierre A Henkart; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

6.  Expression of activation antigens CD69, HLA-DR, interleukin-2 receptor-alpha (IL-2R alpha) and IL-2R beta on T cells of human decidua at an early stage of pregnancy.

Authors:  S Saito; K Nishikawa; T Morii; N Narita; M Enomoto; M Ichijo
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

7.  Expression of CD69 activation marker by endometrial granulated lymphocytes throughout the menstrual cycle and in early pregnancy.

Authors:  N Vassiliadou; J N Bulmer
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

Review 8.  The mother-child union: the case of missing-self and protection of the fetus.

Authors:  W M Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 9.  Daclizumab therapy for multiple sclerosis.

Authors:  Bibiana Bielekova
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 10.  Daclizumab Therapy for Multiple Sclerosis.

Authors:  Bibiana Bielekova
Journal:  Cold Spring Harb Perspect Med       Date:  2019-05-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.